Javed Butler, MD, MPH, MBA, discusses the DAPA ECHO trial data presented at European Society of Cardiology Congress 2024, examining the effects of dapagliflozin on myocardial performance in patients ...
Which mineralocorticoid receptor antagonists (MRAs; ie, steroidal, nonsteroidal) are currently indicated or used for treating heart failure with midrange ejection fraction (HFmrEF) and HF failure ...
"ESC 2024: FINEARTS-HF trial sheds positive light on Kerendia for HFmrEF/HFpEF" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this ...
Experts And Viewpoints, August 30, 2021 ESC 2021 Incremental, Not Monumental, Win for Empagliflozin in HFpEF The modest effects compel clinicians to be selective in the use of this costly drug ...
Medscape Medical News, August 25, 2023 ESC 2023 Wegovy Scores HFpEF Benefits in People With Obesity In STEP-HFpEF, a prospective, randomized study of adults with HFpEF and obesity, weekly ...
Gain practical experience on an industry project and field trip. Ready to take your first step into management? This one-year programme offers the perfect preparation. Taking an in-depth analytical ...
Portfolio management is how you set yourself up for long-term financial success and stability. Learn how to square your own investments with your time horizon and risk tolerance. There’s no one ...
This journal utilises an Online Peer Review Service (OPRS) for submissions. By clicking "Continue" you will be taken to our partner site https://mc.manuscriptcentral ...